Novo Nordisk A/S (NVO)
Business numbers score (revenue, margins, returns) is near the top of its range — how it compares with the broader market is one of its lowest-scoring factors.
NVO scores higher than 57% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Novo Nordisk A/S (NVO) scores 44 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.73× 30-day average
- 52-week range
- 35.12 – 64.16
- Market cap
- —
- Earnings date
- —
- Dividend yield
- 1.00%
- Volume
- 9,645,389
- Avg. volume (30d)
- 13,215,678
- Open
- 38.11
- Previous close
- 38.18
- Day's range (regular session)
- 38.06 – 38.68
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 1.96
- P/E (TTM)
- 9.67
- EPS (TTM)
- 26.18
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about NVO right now
Novo Nordisk A/S (NVO) currently scores 44/100 on the Market Census six-factor composite, at the Average score level. NVO is +1.20% on the day and +3.54% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in NVO's data roughly balance out right now. NVO's strongest factor is company finances at 93/100 — a very strong read on the company's own reported numbers. A high reading doesn't promise a near-term move. The weakest factor is strength vs the market at 18/100 — well below average next to the wider market.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See NVO in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent NVO news
Latest headlines that name Novo Nordisk, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.The Motley Fool
- Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’Yahoo
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Zacks Investment Research
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?Yahoo
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?The Motley Fool
We hide 4 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to NVO’s 44, all within 1 point.
Sorted by closeness to NVO’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.